ARCHIVED: MD Anderson and Affimed announce clinical immuno-oncology development collaboration
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed’s TandAb technology in combination with
MD Anderson’s natural killer cell (NK) product.
NK-cells are white blood cells...
ARCHIVED: Connect to End Cancer launches at South By Southwest 2017 Conference and Festivals
HOUSTON ― The University of Texas MD Anderson Cancer Center, in collaboration with the AT&T Foundry for Connected Health, will launch...
ARCHIVED: Mulva Family Foundation Contributes $75 Million to Fund Patient Care and Research in Neuroscience at UT Austin, Melanoma and Prostate Cancer at MD Anderson
James and Miriam Mulva and the Mulva Family Foundation have donated $50 million to advance neuroscience at The University of Texas at Austin...
ARCHIVED: Older women with breast cancer report better cosmetic satisfaction with less radiation, less surgery
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The University of Texas MD Anderson Cancer Center researchers found that less radiation was associated with improved cosmetic satisfaction long-term. However, reduced radiation was also associated with a slightly increased risk of disease recurrence. ...
ARCHIVED: Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients...
ARCHIVED: MD Anderson affirms Surgeon General’s conclusions on e-cigarette use among youth and young adults
The University of Texas MD Anderson Cancer Center fully supports the United States Surgeon General’s call to action to prevent the use of...
ARCHIVED: MD Anderson Cancer Center, UT Health Northeast Announce Affiliation
UT Health Northeast in Tyler and The University of Texas MD Anderson Cancer Center in Houston today announced a partnership to provide greater...
ARCHIVED: Ronald A. DePinho, M.D., on passage of the 21st Century Cures Act
With strong bipartisan support, the U.S. House and Senate have passed transformative legislation, the 21st Century Cures Act, which will support...
ARCHIVED: Nivolumab with chemotherapy improves response, survival in AML study patients
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival...
ARCHIVED: Research shows patients ineligible for studies may benefit from trial participation
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility...